Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FirsTherapy Plus (Wuhan) Biotech Co., Ltd. is a Chinese biotechnology company specializing in the development and manufacturing of in vitro diagnostic (IVD) products. Based in Wuhan, the company focuses on point-of-care testing (POCT) solutions, utilizing advanced platforms such as fluorescence immunoassay, colloidal gold, and chemiluminescence. Their product portfolio covers a wide range of clinical applications, including cardiovascular diseases, infectious diseases, inflammation, and reproductive health. As a key subsidiary of the publicly traded FirsTherapy (Wuhan) Biotech Co., Ltd., the company provides integrated diagnostic instruments and reagents to healthcare providers globally. FirsTherapy Plus is committed to delivering rapid and accurate diagnostic tools to improve patient outcomes and clinical efficiency.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on FirsTherapy Plus.